UNDERWRITING AGREEMENT between Intensity Therapeutics, Inc. and Roth Capital Partners, LLC as Representative of the Several Underwriters Intensity Therapeutics, Inc.Underwriting Agreement • April 20th, 2022 • Intensity Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
The undersigned, Intensity Therapeutics, Inc., a corporation formed under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Intensity Therapeutics, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with Roth Capital Partners, LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
WARRANT AGENT AGREEMENTWarrant Agent Agreement • April 20th, 2022 • Intensity Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Warrant Agent Agreement (“Warrant Agreement”) is made as of [●], 2022, by and between Intensity Therapeutics, Inc., a Delaware corporation, with offices at 61 Wilton Road, 3rd Floor, Westport, CT 06880 (the “Company”), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company (collectively, the “Warrant Agent”).
